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Summary 
SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients 
with malignant pleural mesothelioma (MPM).  Standard palliative (20Gy/5#) or dose escalated 
treatment (36Gy/6#) will be delivered using advanced radiotherapy techniques and pain responses 
will be compared at week 5. Data will guide optimal palliative radiotherapy in MPM. 
 
Introduction  
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer with a dismal prognosis. [1] As 
there are no curative options, management focuses on palliation. Pain is the most common 
symptom. [2, 3] It is typically dull and diffuse and worsens throughout the course of the disease. [4] 
Aetiology is multifactorial, often including neuropathic and bone related components which can be 
difficult to control, and patients are often on a variety of analgesics with inadequate relief. [5]   
Radiotherapy for pain control is recommended by the British Thoracic Society as a component of 
standard care. [4] Nevertheless, a systematic review conducted in 2014 revealed that only Level 3 
evidence was available to support this practice and highlighted the need for robust and accurate 
symptom response data. [6] We therefore conducted the SYSTEMS study, a multicentre, single arm 
phase II study of conventional dose palliative radiotherapy in MPM (20Gy in 5#), delivered using 
parallel opposing beams. The first prospective study to use validated outcome measures to assess 
pain in MPM, SYSTEMS recruited 40 patients over 18 months and reported clinically significant pain 
responses 5 weeks after radiotherapy in one third of patients, with minimal toxicity. [7] 
We hypothesised that a higher radiation dose would achieve clinically meaningful pain responses in 
a greater proportion of patients and might extend analgesia duration. We will test this hypothesis in 
SYSTEMS-2, which will compare the effects of dose escalated and standard dose radiotherapy on 
pain control in MPM patients. Recognising that dose escalation might increase toxicity, which could 
negate any palliative benefit of the treatment, we will utilise advanced radiotherapy delivery 
  
techniques, predominantly intensity modulated radiotherapy (IMRT), to facilitate dose escalation to 
tumour volumes whilst maintaining acceptable doses to normal tissues.  
Responses to radiotherapy doses can be predicted using the α/β ratio of the tumour. Whilst there 
are little data on which to estimate the α/β ratio of MPM, its relatively low proliferation rate, 
mesenchymal origin and apparent radioresistance are suggestive of a low α/β value. [7] For this 
reason, and to allow palliative treatment to be delivered succinctly, a hypofractionated regime of 
36Gy in 6 fractions over 2 weeks has been selected for the dose escalation arm of SYSTEMS-2.  
 
Methods/Study Design 
SYSTEMS-2 was developed through multidisciplinary collaboration between the Beatson West of 
Scotland Cancer Centre, Edinburgh Cancer Research Centre and the Cancer Research UK Clinical 
Trials Unit Glasgow. The study is sponsored by NHS Greater Glasgow and Clyde and the University of 
Glasgow (GN13ON388). Ethical approval was granted from the National Research Ethics Committee 
on 19th January 2016 (REC number 15/SS/0225). The study complies with Research Governance 
Framework for Health and Community Care, the British Good Clinical Practice regulations and the 
Declaration of Helsinki. The study is registered on the publically available ISRCTN database and is 
badged by the National Institute for Health Research.  
Funding is provided by the June Hancock Mesothelioma Research Fund and Beatson Cancer Charity. 
The translational sample collection is funded by Beatson Cancer Charity, and Slater and Gordon’s 
Health Projects and Research Fund. 
SYSTEMS-2 is a randomised, phase II, multicentre trial comparing two hypofractionated schedules of 
radiotherapy for pain control in MPM: dose escalated (36Gy in 6 fractions over 2 weeks) and 
standard (20Gy in 5 fractions over 1 week).  112 patients in whom radiotherapy is clinically indicated 
for MPM associated pain will be enrolled.  
 
Inclusion criteria: 
 Histological/MDT diagnosis of MPM 
 Performance status 0-2 (ECOG) 
 Predicted life expectance >12 weeks 
 Contrast enhanced CT scan within 8 weeks of starting radiotherapy 
 Worst pain score ≥4/10 after analgesia optimisation 
 Ability to provide written informed consent  
 Willingness to comply with study procedures 
 Radiotherapy plan compatible with the dose escalated arm prior to randomisation  
Exclusion criteria: 
 Patients receiving anti-cancer therapy within 4 weeks of study entry or who are planned for 
anti-cancer therapy within 6 weeks of radiotherapy 
  
 Prior radiotherapy where there is concern that the proposed treatment volume would 
overlap with a previously irradiated area. This does not include patients who have received 
superficial photon or electron therapy to drain sites 
 Psychotic disorders/cognitive impairment 
 Co-existing lung tumours  
 Pregnant/breastfeeding 
 Patients of child-bearing potential, unwilling to use 2 effective methods of contraception.  
 
Study objectives and endpoints 
Primary objective: to establish whether dose escalated, hypofractionated radiotherapy increases the 
proportion of MPM patients experiencing a clinically significant improvement in pain at the site of 
radiotherapy at week 5, compared with standard radiotherapy. Pain will be assessed using the Brief 
Pain Inventory (BPI). A responder will be any patient who has at least a 2 point drop in the ‘worst 
pain score’ component of the BPI, from baseline to week 5. 
Secondary objectives: 
1. Acute toxicity (end of the radiotherapy and weeks 5 and 9) 
2. Overall BPI score and BPI components of average pain, intensity subscale and functional 
interference subscale (weeks 5 and 9) 
3. Radiological response (week 9) 
4. Overall survival (OS) 
5. Quality of life (QoL) at weeks 5 and 9 (assessed by EORTC QLQ-C3O and LC13). 
Exploratory endpoints will include change in strong opioid use, health related QOL at week 9 and 
translational biomarker studies. 
In order to allow the effects of the radiotherapy to be determined accurately, patients must have 
their analgesia optimised prior to randomisation and if necessary should be reviewed by their local 
palliative care team.  
 
Radiotherapy details 
Radio-opaque markers should be used to demarcate painful sites at the time of CT acquisition. 
(Figure 1) 
IMRT is recommended for radiotherapy planning and delivery; however, if this technology is 
unavailable, 3D conformal techniques are acceptable.  The clinical target volume (CTV) will be 
outlined on each slice and should include the area(s) demarcated by wire markers. If there is 
neuropathic pain, the relevant nerve root should be included. The planning target volume (PTV) will 
be formed by adding a 1-2cm margin around the CTV. Relevant organs at risk (OARs) should be 
outlined on each CT slice, depending on tumour position. (Table 1) 
  
While IMRT provides an effective way of manipulating dose distribution, the inverse planning 
process may allow dose to be ‘dumped’ in regions with no maximum specified dose. Therefore, 
OARs must be outlined and allocated an appropriate constraint. 
There are few data to support OAR dose constraints for hypofractionated regimes, particularly in the 
palliative setting. However, relevant data is available for stereotactic ablative radiotherapy, where 
large doses are delivered in small numbers of fractions to limited volumes, often with radical intent.  
[8, 9]  These data have been used to guide development of dose constraints for SYSTEMS-2. (Table 1) 
PTV coverage should not be compromised unless there are clinical concerns that dose(s) to OAR(s) 
would cause unacceptable acute toxicity. In situations where dose constraints cannot be met, it is 
acceptable to reduce the total dose to 30Gy in 5 fractions over 2 weeks. 
Dose will be prescribed using an isocentric technique. Plans should be normalised with 100% 
prescription to the target volume median dose in accordance with ICRU83. Centres unable to 
prescribe to the median dose can alternatively prescribe to the mean dose.  Anticipated PTV 
coverage parameters are shown in Table 1. 
To prevent bias in treatment planning and target volume delineation, radiotherapy planning will 
occur before randomisation. All patients will initially be planned for the dose escalated arm and any 
patient randomised to standard treatment will be re-planned prior to the first fraction. Any patient 
for whom a dose-escalated plan is not achievable will be ineligible. 
Radiotherapy quality assurance will be implemented by the National Radiotherapy Trials QA Group.  
Acute radiation toxicities should be managed with supportive medicines as per local policy. Timings 
and dosages of all analgesics should be recorded. In the event of a pleuritic pain flare, a short course 
of high dose steroids is advised.  
 
Follow up 
The follow up schedule is shown in Figure 2.  After 26 weeks, 2 monthly survival assessments will be 
conducted by the recruiting centre. 
Central radiological review will be led by a Glasgow based consultant radiologist, blinded to the 
delivered radiotherapy dose. Appropriate target lesions will be selected on the basis of the baseline 
CT and radiotherapy plan. Response at week 9 will be reported to Modified RECIST criteria. 
 
Safety reporting 
All Adverse Events (AE) must be recorded in full and include the event nature, start and stop dates, 
severity (graded to CTCAEv4), seriousness and relationship to radiotherapy.  
As the safety profile of radiotherapy is well known, only events that meet the criteria of a Serious 
Adverse Event (SAE), are directly related to the administration of radiotherapy and are not listed as 
expected side effects of radiotherapy (Table 2) require reporting as SAEs.  
  
 
Translational Research 
Patients will be asked to consent to the collection and use of surplus archived formalin-fixed paraffin 
embedded tumour tissue from their original diagnostic biopsy and to the prospective collection of 
blood samples at 3 time-points throughout the trial.   
 
Statistical Analysis 
The study is designed to detect an absolute increase of 20% in the proportion of responders at week 
5 on dose escalated radiotherapy compared to standard radiotherapy from 40% (SYSTEMS [7] 
response rate) to 60%. This requires 112 patients, 56 per arm (comparison of proportions, 90% 
power, 20% 1-sided level of statistical significance; equivalent to 80% power, 10% level of statistical 
significance).  
 Primary efficacy analysis 
The benefit of radiotherapy will be assessed by comparing the proportion of responders at 5 weeks 
between the treatment arms using an adjusted logistic regression model. 
 
 Secondary efficacy analysis 
Analysis of pain response scores and subscales at weeks 5 and 9 and radiological response at week 9 
will use the same approach as the primary efficacy analysis. OS will be compared between the study 
arms using an adjusted Cox model. A Kaplan-Meier curve will illustrate the relative OS. AUC 
techniques will be employed to analyse QoL data.  
 Safety analysis 
The worst recorded toxicity grade for each patient will be summarised by study arm and compared 
using the Mann-Whitney U test.  
 Interim analysis 
The study data will be reviewed annually by an independent data monitoring committee. There will 
be a formal assessment of futility at 50 % recruitment. The 3-outcome design [10] will determine 
whether a phase III study is warranted.  
 
Discussion 
Management of MPM associated pain can be complex and often requires a multidisciplinary 
approach. While chemotherapy is associated with modest survival benefit, there is no evidence that 
it is helpful for pain. [11] Similarly, while surgical procedures can alleviate symptoms such as 
breathlessness, post thoracotomy pain is common and often difficult to manage. [12] Percutaneous 
  
cervical cordotomy appears to be beneficial in selected patients, [13] but  is not widely available and 
there is no prospective randomised evidence to support its role in MPM. 
Palliative radiotherapy can be beneficial for a variety of cancer associated symptoms, particularly 
bone pain. [14] While MPM is generally regarded as radioresistant, palliative doses have long been 
used to alleviate pain. Nevertheless, the majority of evidence behind this practice is of poor quality, 
[6] and the SYSTEMS study provides the only robust evidence that palliative radiotherapy is clinically 
beneficial in a substantial proportion of MPM patients. [7] The question of whether dose escalation 
can improve response rates and prolong pain control has been difficult to address because 2-
dimentional techniques are ill-suited to delivering high radiotherapy doses to the thoracic cavity. 
However, recent advances in radiotherapy planning and delivery have enabled dose escalation while 
maintaining acceptable dose constraints to normal tissues. 
We anticipate that SYSTEMS-2 will provide robust and accurate symptom response data for palliative 
radiotherapy in MPM and help to establish the optimal dose and fractionation in this setting. 
Radiological data will enable further characterisation of radiation responses and their correlations 
with clinical outcome. Furthermore, the associated sample collection will create a unique 
bioresource for future translational research into mesothelioma-specific predictive and response 
biomarkers, which are urgently required.  
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Figure 1. Wire markers denoting the site of pain to aid radiotherapy planning 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
Radiotherapy treatment 
 
Control arm       Treatment arm 
       20Gy in 5 fractions                             30-36Gy in 5-6 fractions 
 over 1 week                        over 2 weeks 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visit 1: Screening 
(Day -28 to day -3) 
 Consent 
 Screening assessments 
 Medication review  
 Registration 
 
Visit 2: Baseline 
(Day -7 to day 1) 
 Routine blood tests (and research bloods if consented) 
 Medication review 
 Physical examination 
 Performance status 
 Study questionnaires 
 Baseline toxicities 
 Randomisation 
Visit 6: Week 26 
 Study questionnaires 
 
Visit 4: Week 5  
 Toxicity assessment 
 Physical examination 
 Performance status 
 Study questionnaires 
 Routine bloods (and research bloods if consented) 
 Medication review 
 
Visit 5: Week 9  
 Toxicity assessment 
 Physical examination 
 Performance status 
 Study questionnaires 
 Routine bloods (and research bloods if consented) 
 Medication review 
 CT scan 
 
Visit 3: Final day of radiotherapy  
 Toxicity assessment 
 Performance status 
 Study questionnaire 
 Medication review 
 
  2 monthly assessment of survival status (no visit required) 
Figure 2: Schedule of events 
  
Table 1. Dose constraints for SYSTEMS-2 
Structure Constraint Maximum dose Indication for delineation 
OARs    
Contralateral lung <5%  
<50% 
<70% 
V20 Gy 
V10 Gy 
V5 Gy 
Any tumour position 
Oesophagus Dmax (0.5 cc) 30 Gy Any tumour position 
Spinal canal Dmax (0.5 cc) 27 Gy Any tumour position 
Trachea and proximal 
bronchus 
Dmax (0.5 cc) 36 Gy Any tumour position 
Heart Dmax (0.5 cc) 36 Gy Any tumour position 
Liver Mean Liver Dose 16 Gy Low lying right sided tumours 
where >700cc of liver scanned 
Kidneys (individual and 
combined) 
Mean kidney dose 
 
10 Gy 
 
Low lying tumours 
If solitary kidney or if 
one kidney mean dose 
>10Gy 
<45% V10 Gy  Low lying tumours 
Stomach Dmax (0.5 cc) 30 Gy Low lying left sided tumours 
Great Vessels Dmax (0.5 cc) 36 Gy Any tumour position 
Small bowel Dmax (0.5 cc) 30 Gy Low lying tumours 
Ipsilateral Brachial 
Plexus 
Dmax (0.5 cc) 36 Gy PTV above T2 
Large bowel Dmax (0.5cc) 30 Gy Low lying tumours 
PTV    
Minimum D98% >95%   
Median D50% 100%  
Maximum D2% <107%  
 
  
Table 2. Expected side effects of radiotherapy 
Pulmonary haemorrhage Pneumonitis 
Oesophageal candidiasis Dermatitis radiation 
Anaemia Pulmonary fistula 
White blood cell decreased Carbon monoxide diffusing capacity 
decreased 
Neutrophil count decreased Forced expiratory volume decreased 
Nausea Vital capacity abnormal 
Vomiting Cardiac toxicity (pericardial disease or 
myocardial infarction) 
Constipation Spinal cord toxicity 
Fatigue Late oesophageal stricture 
Febrile neutropenia Late radiation fibrosis 
Neutropenic sepsis RT induced rib fracture 
Lung infection Late malignancy within the radiation field 
Oesophagitis Pleuritic pain flare 
 
 
  
  
 A randomised phase II trial of radiotherapy dose escalation for pain control in MPM 
 Comparison of 2 hypofractionated regimes (20Gy/5# and 36Gy/6#) 
 Highly conformal radiotherapy techniques used to aid safe dose escalation 
 Primary outcome: pain control at week 5 at radiotherapy site 
 Secondary endpoints: acute toxicity, radiological response, quality of life 
 Recruitment target: 112 patients from 10-15 UK centres 
 
